Source: Cyclo Therapeutics, Inc. 10/23/19
White House Announcement made on October 22, 2019
Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology
company that develops cyclodextrin-based products for the treatment of
diseases with unmet medical need, including Niemann-Pick Disease Type C
and Alzheimer’s Disease, today announced that Sharon H. Hrynkow, Ph.D.,
its Chief Scientific Officer and Senior Vice President for Medical
Affairs, has been appointed to the President’s Council of Advisors on
Science and Technology (PCAST). On October 22, President Donald J. Trump
signed an executive order re-chartering PCAST and announced the first
seven members, including Dr. Hrynkow.
Dr. Hrynkow, a neuroscientist by training, has served in executive
leadership roles at the National Institutes of Health, as the inaugural
President of the Global Virus Network, a non-profit organization, and as
Senior Science Advisor at the Department of State. Dr. Hrynkow leads
the Cyclo Therapeutics, Inc. clinical and scientific programs developing
the company’s drug, Trappsol® Cyclo™, for treatment of
Niemann-Pick Disease Type C, a rare and fatal disease in children, and
for Alzheimer’s Disease. She is Co-Chair of the Company’s Scientific
Advisory Board.
A total of 16 members are expected to be appointed to PCAST. Dr. Kelvin
Droegemeier, Director of The White House Office of Science and
Technology, will chair the Council. See the full announcement HERE.
“Under this Administration, science and technology in America continues
to advance by leaps and bounds. PCAST will be critical to our continued
efforts, with each member bringing a unique perspective to the table. By
convening a diverse group of our Nation’s foremost leaders across a
broad range of fields, we can leverage the full innovation ecosystem,
solve some of the Nation’s greatest challenges, and ensure America’s
science and technology leadership for generations to come,” said Dr.
Droegemeier.
“Advances in science and technology are major drivers of US economic
growth and they contribute to our nation’s security,” said Dr. Hrynkow.
“I am delighted to serve on PCAST to work with colleagues across many
disciplines to find solutions to critical science and technology
challenges facing our nation.”
“We are all very proud to see Dr. Hrynkow appointed to PCAST, and we
know that she will serve with distinction,” said Company Chairman and
CEO, N. Scott Fine.
About Cyclo Therapeutics:
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that
develops cyclodextrin-based products for the treatment of disease. The
company’s Trappsol® Cyclo™, an orphan drug designated product
in the United States and Europe, is in three ongoing formal clinical
trials for Niemann-Pick Disease Type C, a rare and fatal genetic
disease, (Clinical Trials.gov NCT02939547, NCT02912793 and NCT03893071) and in an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company’s website: www.cyclotherapeutics.com
About PCAST:
PCAST was launched by Executive Order in 2001, formalizing a process
that had been in place through many previous Administrations to advise
the President on matters involving science, technology, education, and
innovation policy. The Council provides the President with scientific
and technical information that is needed to inform public policy
relating to the American economy, the American worker, national and
homeland security, and other topics. The Council includes distinguished
individuals from sectors outside of the Federal Government and
represents diverse perspectives and expertise in science, technology,
education and innovation.
No comments:
Post a Comment